UK companyGW Pharmaceuticalsare seeing booming sales of their 'Sativex' oral spray which has led to a 16% rise in revenues. GW have UK Government approval to grow cannabis on an industrial scale in their UK headquarters which is then converted into an oral spray which contains a balanced formula of 1:1, THC:CBD.
The initial intention was to sell the 'Sativex' spray for treatment of MS (Multiple Sclerosis), but more recently the firm (and its investors) are increasingly excited by the possibility of using Sativex for relief of advanced cancer pain. GW Pharma are currently working their way through the third phase of testing in the USA for cancer pain relief with good results. On top of that they have successfully completed a listing on the NASDAQ stock exchange which has raised important cash for future 'growth'.
Sativex is sold in 21 countries, with more expected to join the list soon. Many investors are expecting to see significant sales of legal cannabis medicines as continued medical research highlights the growing uses of medical marijuana.
June 4th 2013